- CV Sciences press release ( OTCQB:CVSI ): Q2 Non-GAAP EPS of -$0.02 beats by $0.01 .
- Revenue of $4.1M (-20.1% Y/Y) misses by $0.78M .
- Gross margin of 30.7% for second quarter of 2022, compared to 44.7% for the second quarter of 2021;
- Total cash balance of $1.1 million at quarter end, compared to $1.4 million at year end;
- Launched PlusCBD™ Relief softgels to our wellness line of products joining our successful PlusCBD™ Sleep and Calm gummies;
- Regained position as top-selling hemp extract brand in the natural product retail sales channel, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry;
- Continued to evaluate strategic review, including consideration of inbound and outbound merger, sale, acquisition or other options for the Company as a whole or for any business segments;
- Reduced operating expenses by 38.2% compared to the second quarter of 2021; and
- Completed move to more efficient and cost effective facility in San Diego.
For further details see:
CV Sciences Non-GAAP EPS of -$0.02 beats by $0.01, revenue of $4.1M misses by $0.78M